PROSTAGLANDIN ANALOGS AND USES THEREOF

The present invention relates to a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effec...

Full description

Saved in:
Bibliographic Details
Main Authors RAJAN, Sreekanth, YOON, Ho Sup, YOON, Cheolhwan, KIM, Moonhwan, SEO, Jeongbeob, HAN, Cheolkyu, KANG, Hongjun, YOO, Jun Yeob
Format Patent
LanguageEnglish
French
Published 14.05.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically acceptable salt thereof, wherein the compound has excellent effects in inducing Nurr1, and thus, can be useful as a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, in particular, cancer, autoimmune disease such as rheumatoid arthiritis, schizophrenia, manic depression and neurodegenerative disease such as Alzheimers disease or Parkinson's disease. La présente invention concerne une composition pharmaceutique pour la prévention ou le traitement d'une maladie, trouble, ou un état associé à Nurr1, comprenant, en tant que principe actif, un analogue de prostaglandine ou un sel pharmaceutiquement acceptable de celui-ci, le composé ayant d'excellents effets dans l'induction de Nurr1, et peut ainsi être utile en tant que composition pharmaceutique pour la prévention ou le traitement d'une maladie, de troubles ou d'états associés à Nurr1, en particulier, le cancer, les maladies auto-immunes telles que la polyarthrite rhumatoïde, la schizophrénie, la dépression maniaque et les maladies neurodégénératives telles que la maladie d'Alzheimer ou la maladie de Parkinson.
Bibliography:Application Number: WO2020KR15655